BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia (2023)
- Authors:
- USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; ICB
- DOI: 10.1042/BCJ20210608
- Subjects: IMUNOLOGIA; LEUCEMIA MIELOIDE AGUDA; NEOPLASIAS POR TIPO HISTOLÓGICO; PROTEÍNAS QUINASES
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Biochemical Journal
- ISSN: 1470-8728
- Volume/Número/Paginação/Ano: v. 480, p. 161–176, 2023
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
BRUMATTI, Gabriela et al. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, v. 480, p. 161–176, 2023Tradução . . Disponível em: https://doi.org/10.1042/BCJ20210608. Acesso em: 01 abr. 2026. -
APA
Brumatti, G., Kaloni, D., Castro, F. A. de, & Amarante-Mendes, J. G. P. (2023). BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, 480, 161–176. doi:10.1042/BCJ20210608 -
NLM
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1042/BCJ20210608 -
Vancouver
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1042/BCJ20210608 - Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- Apoptotic genes expression in head and neck squamous cell carcinoma (HNSCC) patients
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
- Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003124200.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
